690 — Uni-Bio Science Share Price
Last trade - 00:00- HK$456.11m
- HK$383.17m
- HK$484.72m
- 55
- 77
- 43
- 64
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.77 | ||
| Price to Tang. Book | 2.09 | ||
| Price to Free Cashflow | 11.66 | ||
| Price to Sales | 0.94 | ||
| EV to EBITDA | 4.16 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 25.98% | ||
| Return on Equity | 31.37% | ||
| Operating Margin | 15.82% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | HK$m | 209.45 | 208.78 | 353.4 | 440.32 | 484.72 | n/a | n/a | 29.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +73.95 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Uni-Bio Science Group Limited is a Hong Kong-based investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.
Directors
- Leung Kingsley CHM (31)
- Zhi Gang Zhao CEO (59)
- Dawei Chen VCH (47)
- You Hoi Kong GMG (48)
- Shun Tai Chan OTH (54)
- Wei Yue Han OTH (48)
- Phee Wah Koh OTH (56)
- Yan Liu OTH (42)
- Chang Qing Luo OTH (52)
- Ya Lei Wen OTH (55)
- Shibin She SEC
- Kwok Wing Yau NED (46)
- Kai Ming Chow NID (50)
- Qingshan Ma NID (39)
- Qimin Ren NID (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 20th, 2001
- Public Since
- November 12th, 2001
- No. of Employees
- 407
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 6,163,588,147
- Address
- 13/F, Public Bank Centre,
- Web
- https://www.uni-bioscience.com/
- Phone
- +852 null31023232
- Auditors
- BDO LTD
Upcoming Events for 690
Similar to 690
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 18:34 UTC, shares in Uni-Bio Science are trading at HK$0.07. This share price information is delayed by 15 minutes.
Shares in Uni-Bio Science last closed at HK$0.07 and the price had moved by +15.63% over the past 365 days. In terms of relative price strength the Uni-Bio Science share price has outperformed the FTSE Developed Asia Pacific Index by +10.29% over the past year.
There is no consensus recommendation for this security.
Uni-Bio Science does not currently pay a dividend.
Uni-Bio Science does not currently pay a dividend.
Uni-Bio Science does not currently pay a dividend.
To buy shares in Uni-Bio Science you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$0.07, shares in Uni-Bio Science had a market capitalisation of HK$456.11m.
Here are the trading details for Uni-Bio Science:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 690
Based on an overall assessment of its quality, value and momentum Uni-Bio Science is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Uni-Bio Science. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +58.6%.
As of the last closing price of HK$0.07, shares in Uni-Bio Science were trading +10.83% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Uni-Bio Science PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Uni-Bio Science's management team is headed by:
- Leung Kingsley - CHM
- Zhi Gang Zhao - CEO
- Dawei Chen - VCH
- You Hoi Kong - GMG
- Shun Tai Chan - OTH
- Wei Yue Han - OTH
- Phee Wah Koh - OTH
- Yan Liu - OTH
- Chang Qing Luo - OTH
- Ya Lei Wen - OTH
- Shibin She - SEC
- Kwok Wing Yau - NED
- Kai Ming Chow - NID
- Qingshan Ma - NID
- Qimin Ren - NID